Methotrexate (RASUVO) – USA

Methotrexate (RASUVO) – USA


IPR decision (February 7, 2018):

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Status
IPR2016-01370
July 20, 2016
Feb 8, 2017
Koios Pharmaceuticals LLC
US 8,664,231
Final Written Decision
(claims 1–22 are patentable)
On US’231 patent, Antares & Frontier Therapeutic previously filed IPRs (IPR2014-01091 & IPR2016-00649) which were terminated by PTAB.
US 8,664,231 (Medac; 06/01/2029) – OB listed

1. A method for the treatment of inflammatory autoimmune diseases in a patient in need thereof, comprising subcutaneously administering to said patient a medicament comprising methotrexate in a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved